Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $12.6 billion biopharmaceutical company with robust financial health according to InvestingPro analysis, presented new analyses showing significant improvements in health-related quality of life among adults aged 65 and older with tardive dyskinesia who received continued treatment with INGREZZA (valbenazine) capsules.
The findings, presented at the 2025 American Association of Nurse Practitioners National Conference, come from post-hoc analyses of a Phase 4 randomized withdrawal study involving 29 older adults. Patients who continued INGREZZA treatment reported significant improvements in health-related quality of life and functional status compared to those switched to placebo. The company’s strong commercial execution has led to impressive 21.7% revenue growth over the last twelve months, with eight analysts recently revising their earnings expectations upward, as reported by InvestingPro.
The analyses used two clinically validated assessment tools: the EuroQol 5-Dimension 5-Level assessment, which measures health status across five dimensions, and the Sheehan Disability Scale, which measures functional impairment in work, social life, and family life.
"Older adults are not only at increased risk for developing tardive dyskinesia, but are also more susceptible to the profound physical, functional and social consequences of their uncontrolled movements," said Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences.
These results add to previous findings from the company’s KINECT-PRO study, which demonstrated clinically meaningful improvement in patient-reported impact of tardive dyskinesia with INGREZZA treatment.
Tardive dyskinesia is a movement disorder characterized by uncontrolled, abnormal movements of the face, torso, and other body parts. It is associated with certain mental health medications that affect dopamine receptors in the brain and is estimated to affect at least 800,000 adults in the U.S.
INGREZZA is a selective vesicular monoamine transporter 2 inhibitor approved for treating tardive dyskinesia in adults and chorea associated with Huntington’s disease.
The information in this article is based on a company press release statement. With a healthy current ratio of 3.13 and strong profitability metrics, Neurocrine Biosciences demonstrates solid operational execution. For deeper insights into NBIX’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Neurocrine Biosciences, Inc. has reported positive results from a Phase 2 clinical trial involving their investigational drug, NBI-1117568, for schizophrenia. The trial demonstrated significant improvements in symptoms, with the 20 mg dosage showing notable benefits as early as the third week. Following these encouraging results, Neurocrine has initiated a Phase 3 registrational program to further evaluate the drug’s efficacy and safety. In another development, Guggenheim analysts have maintained a Buy rating for Neurocrine, citing optimism about the company’s growth prospects and ongoing clinical programs. RBC Capital also reaffirmed an Outperform rating, emphasizing confidence in the company’s prescription growth and market stability for its product, Ingrezza. Additionally, Lewis Choi has been appointed as the new Chief Information Officer at Neurocrine Biosciences, bringing extensive experience in information technology and artificial intelligence. These developments reflect ongoing advancements and strategic leadership changes at Neurocrine Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.